AI assistant
Panacea Biotec Ltd. Capital/Financing Update 2021
62573_rns_2021-08-05_489f1fdc-08c4-4ca6-a54b-f35fce411328.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
August 5, 2021
The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol: PANACEABIO
BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001 BSE Scrip Code: 531349
Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Dear Sir/Madam,
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we are pleased to inform you that the Company has, on August 3,2021, entered into a Licensing and Manufacturing Agreement with Human Vaccine Limited Liability Company, a subsidiary of Russian Direct Investment Fund, Russia, GENERIUM Joint Stock Company and Dr. Reddy's Laboratories Limited.
The detailed disclosure as required under Regulation 30 ofSEBI LODR Regulations in respect of the above mentioned matter is as follows:
| S.No. | Particulars | Description |
|---|---|---|
| 1. | Name of parties with whom theagreement is entered | HumanVaccineLimitedLiability1.Company, a subsidiary of Russian DirectInvestment Fund, Russia ("RDIF")GENERIUMJointStock Company,2.Russia ("Generium")3. Dr. Reddy's Laboratories Limited. ("Dr.Reddy's") |
| 2. | ofPurposeenteringintoagreement | the As per the terms of this Agreement, PanaceaBiotec shall produce Covid-19 vaccineSputnik V using the ready to fill drugsubstance manufactured by Generium inRussia, and then supply the entire quantitythereof to Dr. Reddy's for distribution inIndia. |
91 Extn./G3, Mohan Co-op Indl. Estate, Mathura Road, New Delhi -110044 Email: [email protected] Phone: 0.1.0. +91-114167 901~ Fax: +91-1141679070
Page 1 of2
Panacea Biotec Ltd.
CIN:L33117PB1984PLC022350 Registered Office: Ambala-Chandigarh Highway, Lalru - 140501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906. e-mail: [email protected] website: www.panaceabiotec.com
| S. No. | Particulars | Description |
|---|---|---|
| 3. | Size of agreement | The agreement is for manufacture (fill andfinish) of upto 25 million doses of Sputnik Vvaccine. |
| Other details are confidential in nature andhence can't be disclosed. | ||
| 4. | Shareholding, if any, in the entity Nilwith whom the agreement is executed | |
| 5. | Significant terms of the agreement (in Nilbrief) special rights like right toappoint directors, first right to sharesubscription in case of issuance ofshares, right to restrict any change incapital structure etc. | |
| 6. | Whether, the said parties are related to Nopromoter / promoter group / groupcompanies in any manner. If yes,nature of relationship | |
| 7. | Whether the transaction would fall Nowithin related party transactions? Ifyes, whether the same is done at"arms' length" | |
| 8. | In case of issuance of shares to the N.A.parties, details of issue price, class ofshares issued | |
| 9. | Any other disclosures related to such N.A.agreements, viz., details of nomineeon the board of directors of the listedentity, potential conflict of interestarising out of such agreements, etc. |
This is for your kind information and record please.
Thanking you,
Sincerely yours, ./,j~~,_ for Panacea Biotec Ltd. «:r~: ; '
V~ ~ Vinod Goel '., ~ Group CFO If"~ ffe~d Legal & Company Secretary
Page 2 of2